Recently the rights issue got a fillip, after Dilip Shanghvi, the Managing Director of Sun Pharmaceutical Industries expressed his willingness to the promoters of the company to fully participate in the upcoming Rs 1,200-cr rights issue. In the past, Shanghvi had bought a 23 per cent stake in Suzlon for Rs 1,800 crore in 2015, helping the company to return to profitability after it became India’s largest convertible-bond defaulter in 2012. READ MORE
Also read: Suzlon Energy charts course to return to its pre-2007 boom days
To read the full story, Subscribe Now at just Rs 249 a month
Already a subscriber? Log in
Subscribe To BS Premium
₹249
Renews automatically
₹1699₹1999
Opt for auto renewal and save Rs. 300 Renews automatically
₹1999
What you get on BS Premium?
- Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
- Pick your 5 favourite companies, get a daily email with all news updates on them.
- Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
- Preferential invites to Business Standard events.
- Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
Need More Information - write to us at assist@bsmail.in